BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11675522)

  • 21. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
    Caggiano V; Weiss RV; Rickert TS; Linde-Zwirble WT
    Cancer; 2005 May; 103(9):1916-24. PubMed ID: 15751024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Annual productivity costs due to cervical cancer mortality in the United States.
    Insinga RP
    Womens Health Issues; 2006; 16(5):236-42. PubMed ID: 17055376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of neutropenic complications of chemotherapy.
    Weycker D; Malin J; Edelsberg J; Glass A; Gokhale M; Oster G
    Ann Oncol; 2008 Mar; 19(3):454-60. PubMed ID: 18083689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
    Tai E; Guy GP; Dunbar A; Richardson LC
    J Oncol Pract; 2017 Jun; 13(6):e552-e561. PubMed ID: 28437150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment.
    Lathia N; Isogai PK; Walker SE; De Angelis C; Cheung MC; Hoch JS; Mittmann N
    Support Care Cancer; 2013 Jan; 21(1):245-51. PubMed ID: 22684150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    Russo A; Autelitano M; Bisanti L
    J Natl Cancer Inst; 2006 Dec; 98(24):1826-7. PubMed ID: 17179484
    [No Abstract]   [Full Text] [Related]  

  • 32. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas.
    Costa VC; Ferraz MB; Petrilli AS; Pereira CA; Rogerio JW
    Support Care Cancer; 2003 Jun; 11(6):356-61. PubMed ID: 12720070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
    Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
    J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    Hassett MJ; O'Malley AJ; Pakes JR; Newhouse JP; Earle CC
    J Natl Cancer Inst; 2006 Aug; 98(16):1108-17. PubMed ID: 16912263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities.
    Paner A; Okwuosa TM; Richardson KJ; Libby EN
    Expert Rev Hematol; 2018 Dec; 11(12):957-973. PubMed ID: 30339769
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.